Fibroblast Growth Factor 23 Bone Regulation and Downstream Hormonal Activity

Overview

Journal Calcif Tissue Int

Specialty Pathology

Date 2023 Jun 12

PMID 37306735

Authors

Erica Clinkenbeard

Affiliations

Soon will be listed here.

Abstract

Mineral homeostasis of calcium and phosphate levels is one critical component to the maintenance of bone mineral density (BMD) and strength. Diseases that disrupt calcium and phosphate balanced have highlighted not only the role these minerals play in overall bone homeostasis, but also the factors, hormones and downstream transporters, responsible for mineral metabolism. The key phosphaturic hormone elucidated from studying rare heritable disorders of hypophosphatemia is Fibroblast Growth Factor 23 (FGF23). FGF23 is predominantly secreted from bone cells in an effort to maintain phosphate balance by directly controlling renal reabsorption and indirectly affecting intestinal uptake of this mineral. Multiple factors have been shown to enhance bone mRNA expression; however, FGF23 can also undergo proteolytic cleavage to control secretion of the biologically active form of the hormone. The review focuses specifically on the regulation of FGF23 and its secretion from bone as well as its hormonal actions under physiological and disease conditions.

Citing Articles

Distinct role of Klotho in long bone and craniofacial bone: skeletal development, repair and regeneration.

Chen X, Wei Y, Li Z, Zhou C, Fan Y PeerJ. 2024; 12:e18269.

PMID: 39465174 PMC: 11505971. DOI: 10.7717/peerj.18269.

Inherited phosphate and pyrophosphate disorders: New insights and novel therapies changing the oral health landscape.

Foster B, Boyce A, Millan J, Kramer K, Ferreira C, Somerman M J Am Dent Assoc. 2024; 155(11):912-925.

PMID: 39127957 PMC: 11540754. DOI: 10.1016/j.adaj.2024.05.016.

The role of fibroblast growth factor 23 in regulation of phosphate balance.

Wilson R, Mukherjee-Roy N, Gattineni J Pediatr Nephrol. 2024; 39(12):3439-3451.

PMID: 38874635 DOI: 10.1007/s00467-024-06395-5.

The Skeleton as a Secretory Organ.

Bidwell J, Bonewald L, Robling A Calcif Tissue Int. 2023; 113(1):1-3.

PMID: 37393315 DOI: 10.1007/s00223-023-01106-y.

Messages from the Mineral: How Bone Cells Communicate with Other Tissues.

Plotkin L, Sanz N, Brun L Calcif Tissue Int. 2023; 113(1):39-47.

PMID: 37171619 PMC: 10330496. DOI: 10.1007/s00223-023-01091-2.

References

Yamazaki M, Michigami T . Osteocytes and the pathogenesis of hypophosphatemic rickets. Front Endocrinol (Lausanne). 2022; 13:1005189. PMC: 9556901. DOI: 10.3389/fendo.2022.1005189. View

Raggatt L, Partridge N . Cellular and molecular mechanisms of bone remodeling. J Biol Chem. 2010; 285(33):25103-8. PMC: 2919071. DOI: 10.1074/jbc.R109.041087. View

Shigematsu T, Horiuchi N, Ogura Y, Miyahara T, Suda T . Human parathyroid hormone inhibits renal 24-hydroxylase activity of 25-hydroxyvitamin D3 by a mechanism involving adenosine 3',5'-monophosphate in rats. Endocrinology. 1986; 118(4):1583-9. DOI: 10.1210/endo-118-4-1583. View

Silver J, Kilav R, Naveh-Many T . Molecular mechanisms of secondary hyperparathyroidism. Pediatr Nephrol. 2000; 14(7):626-8. DOI: 10.1007/s004670000355. View

Zhao N, Tenenhouse H . Npt2 gene disruption confers resistance to the inhibitory action of parathyroid hormone on renal sodium-phosphate cotransport. Endocrinology. 2000; 141(6):2159-65. DOI: 10.1210/endo.141.6.7484. View

Estepa J, Aguilera-Tejero E, Lopez I, Almaden Y, Rodriguez M, Felsenfeld A . Effect of phosphate on parathyroid hormone secretion in vivo. J Bone Miner Res. 1999; 14(11):1848-54. DOI: 10.1359/jbmr.1999.14.11.1848. View

Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K . Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology. 2002; 143(8):3179-82. DOI: 10.1210/endo.143.8.8795. View

White K, Jonsson K, Carn G, Hampson G, Spector T, Mannstadt M . The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab. 2001; 86(2):497-500. DOI: 10.1210/jcem.86.2.7408. View

White K, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom T, Econs M . Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 2001; 60(6):2079-86. DOI: 10.1046/j.1523-1755.2001.00064.x. View

10.

Econs M, McEnery P, Lennon F, Speer M . Autosomal dominant hypophosphatemic rickets is linked to chromosome 12p13. J Clin Invest. 1998; 100(11):2653-7. PMC: 508467. DOI: 10.1172/JCI119809. View

11.

Yu X, White K . FGF23 and disorders of phosphate homeostasis. Cytokine Growth Factor Rev. 2005; 16(2):221-32. DOI: 10.1016/j.cytogfr.2005.01.002. View

12.

Riminucci M, Collins M, Fedarko N, Cherman N, Corsi A, White K . FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest. 2003; 112(5):683-92. PMC: 182207. DOI: 10.1172/JCI18399. View

13.

Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T . Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab. 2002; 87(11):4957-60. DOI: 10.1210/jc.2002-021105. View

14.

Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse H . Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology. 2004; 145(7):3087-94. DOI: 10.1210/en.2003-1768. View

15.

Sitara D, Razzaque M, Hesse M, Yoganathan S, Taguchi T, Erben R . Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 2004; 23(7):421-32. PMC: 2894977. DOI: 10.1016/j.matbio.2004.09.007. View

16.

Clinkenbeard E, Cass T, Ni P, Hum J, Bellido T, Allen M . Conditional Deletion of Murine Fgf23: Interruption of the Normal Skeletal Responses to Phosphate Challenge and Rescue of Genetic Hypophosphatemia. J Bone Miner Res. 2016; 31(6):1247-57. PMC: 4891276. DOI: 10.1002/jbmr.2792. View

17.

Saito H, Kusano K, Kinosaki M, Ito H, Hirata M, Segawa H . Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production. J Biol Chem. 2002; 278(4):2206-11. DOI: 10.1074/jbc.M207872200. View

18.

Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y . FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004; 19(3):429-35. DOI: 10.1359/JBMR.0301264. View

19.

Heijboer A, Cavalier E . The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) Concentrations. Calcif Tissue Int. 2022; 112(2):258-270. PMC: 9859838. DOI: 10.1007/s00223-022-00987-9. View

20.

Tagliabracci V, Engel J, Wiley S, Xiao J, Gonzalez D, Appaiah H . Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis. Proc Natl Acad Sci U S A. 2014; 111(15):5520-5. PMC: 3992636. DOI: 10.1073/pnas.1402218111. View